It was first characterized by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s, and a 2025 literature and patent review cataloged its effects across gastrointestinal, musculoskeletal, and neural models
Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, AbbVie, Adamed, Alcediag, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Casen-Recordati, Celon Pharma, Clariane, Compass, Dainippon Sumitomo Pharma, Esteve, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Intra-Cellular therapies, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Mitsubishi Tanabe Pharma, Newraxpharm, Newron, Novartis, Organon, Orion Corporation, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris, outside the submitted work
Chemically Characterized : Each peptide undergoes rigorous analytical verification, including HPLC purification, mass spectrometry confirmation, and chromatographic purity assessment to ensure lot-specific quality documentation
Its cytoprotective effects were first characterized in the GI tract, but subsequent research has extended these findings to tendons, ligaments, bone, muscle, and even neural tissue